Transaction details
On March 24, 2026, Paula Soteropoulos, a director at Dianthus Therapeutics (NASDAQ:DNTH), sold 27,594 shares of the company's common stock at $78.05 per share, producing $2.15 million in gross proceeds from the sale. The same day she exercised stock options to acquire 27,594 shares at an exercise price of $8.44 per share, for a total cash outlay of $232,893. Following these transactions Soteropoulos directly holds 0 shares of Dianthus common stock.
Context on the equity and valuation
The sale occurred while the stock was trading close to its 52-week high of $88.02, after a 351% return over the prior 12 months. InvestingPro analysis cited in company filings indicates the share price appears overvalued relative to its Fair Value estimate.
Options and plan mechanics
The exercised awards relate to stock options that vest according to a set schedule: 25% vested on April 6, 2023, with the remaining portion vesting in equal monthly installments over the subsequent three years. Both the sale and the option exercise were carried out under a pre-arranged Rule 10b5-1 trading plan that Soteropoulos adopted on December 23, 2025.
Capital raise and market activity
Separately, Dianthus closed a major public offering that generated approximately $719 million in gross proceeds. That transaction involved the sale of 8,470,989 shares of common stock at $81.00 per share, inclusive of shares sold through the exercise of underwriters' options. In connection with the offering the company also issued pre-funded warrants allowing for the purchase of up to 402,468 shares at a near-equivalent price; those pre-funded warrants are immediately exercisable.
Analyst responses and clinical/regulatory developments
Analysts have actively reassessed the stock around recent regulatory and clinical updates. William Blair reiterated an Outperform rating after an FDA update that removed certain screening criteria related to antinuclear antibodies, a change described as addressing concerns about potential drug-induced lupus. William Blair also reiterated its Outperform view based on interim results from the CAPTIVATE study in chronic inflammatory demyelinating polyneuropathy, citing competitive efficacy and safety outcomes that could position the treatment as a frontline option.
Wells Fargo maintained its Overweight rating on the stock and set a $135.00 price target.
Investor resources
The public notes accompanying the filings reference InvestingPro, which offers 15 additional exclusive tips for DNTH along with a suite of financial metrics intended to support investor decision-making.
Bottom line
The director-level sale and simultaneous option exercise, the recent large equity raise and ongoing analyst coverage combine to keep DNTH in focus for investors. The sale was executed under an established trading plan and follows a period of substantial share-price appreciation, while the company continues to advance clinical programs and manage its balance sheet through the public offering.